Active, not recruitingPhase 2NCT04006522

89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

Studying Hereditary clear cell renal cell carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
James Brugarolas
Principal Investigator
James Brugarolas, MD, PhD, MD
University of Texas Southwestern Medical Center
Intervention
89Zr-DFO-Atezolizumab(drug)
Enrollment
46 enrolled
Eligibility
18 years · All sexes
Timeline
20192026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04006522 on ClinicalTrials.gov

Other trials for Hereditary clear cell renal cell carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Hereditary clear cell renal cell carcinoma

← Back to all trials